Novo's Sogroya receives FDA approval
NVO•Novo said Sogroya received FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner syndrome.
1. FDA approval
Novo said Sogroya received FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner syndrome.




